Imatinib mesylate for the treatment of pulmonary arterial hypertension (Q37954724)

25 August 2017

Imatinib mesylate for the treatment of pulmonary arterial hypertension (English)

1 reference

25 August 2017

arterial hypertension

0 references

1 reference

Henrik ten Freyhaus

1

1 reference

25 August 2017

Daniel Dumitrescu

2

1 reference

25 August 2017

Eva Berghausen

3

1 reference

25 August 2017

Marius Vantler

4

1 reference

25 August 2017

Evren Caglayan

5

1 reference

25 August 2017

Stephan Rosenkranz

6

1 reference

25 August 2017

language of work or name

English

0 references

publication date

11 November 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

1 reference

25 August 2017

21

1 reference

25 August 2017

119-134

1 reference

25 August 2017

1

1 reference

Diagnosis and assessment of pulmonary arterial hypertension.

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Pulmonary hypertension: current diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Updated clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Inflammation, growth factors, and pulmonary vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Cellular and molecular basis of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Genetic basis of pulmonary arterial hypertension: current understanding and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Genetics and genomics of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Development and pathology of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Hypoxic activation of adventitial fibroblasts: role in vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Pulmonary hypertension and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Efficacy and optimal dose of sildenafil in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Oscillatory shear stress increases smooth muscle cell proliferation and Akt phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

PDGF and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

PDGF receptor and its antagonists: role in treatment of PAH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Receptor tyrosine kinases and their targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

PDGF receptor kinase inhibitors for the treatment of restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase Cγ 1 activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

PDGF and microvessel wall remodeling in adult rat lung: imaging PDGF-AA and PDGF-Ralpha molecules in progenitor smooth muscle cells developing in experimental pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Heterotrimeric G proteins and the platelet-derived growth factor receptor-beta contribute to hypoxic proliferation of smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

PDGF-D, a new protease-activated growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Platelet-derived growth factor receptor beta signaling is required for efficient epicardial cell migration and development of two distinct coronary vascular smooth muscle cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Retention of PDGFR-beta function in mice in the absence of phosphatidylinositol 3'-kinase and phospholipase Cgamma signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Growth factor signaling pathways in vascular development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Phosphatidylinositol 3-kinase-dependent membrane recruitment of Rac-1 and p47phox is critical for alpha-platelet-derived growth factor receptor-induced production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Platelet-derived growth factor-dependent cellular transformation requires either phospholipase Cgamma or phosphatidylinositol 3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase binding sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Regulation of chemotaxis by the platelet-derived growth factor receptor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

The platelet-derived growth factor beta receptor triggers multiple cytoplasmic signaling cascades that arrive at the nucleus as distinguishable inputs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

The GTPase-activating protein of Ras suppresses platelet-derived growth factor beta receptor signaling by silencing phospholipase C-gamma 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Tyrosine phosphatases in vessel wall signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Metabolism and disposition of imatinib mesylate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3'-kinase is important

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Long term imatinib treatment in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.632408

10.1517/13543784.2012.632408

21 January 2018

Identifiers

DOI

1 reference

release_3k73s5mfkzgijdyowjqwk2mfxy

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3k73s5mfkzgijdyowjqwk2mfxy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference